Association between δ-aminolevulinate dehydratase G177C polymorphism and blood lead levels in brain tumor patients

Taha,Mahmoud  Mostafa; Gaber,Osama   Abd El Aziz; Sabbah,Norhan  Abdalla; Abd Elazem,Abd Allah  S

doi:10.3892/mco.2015.589

Association between δ-aminolevulinate dehydratase G177C polymorphism and blood lead levels in brain tumor patients

Authors:
- Mahmoud Mostafa Taha
- Osama Abd El Aziz Gaber
- Norhan Abdalla Sabbah
- Abd Allah S Abd Elazem
View Affiliations

Affiliations: Department of Neurosurgery, Faculty of Medicine, Zagazig University, Zagazig 44512, Egypt, Department of Medical Biochemistry, Faculty of Medicine, Zagazig University, Zagazig 44512, Egypt, Department of Medical Biochemistry, Faculty of Medicine, Al‑Azhar University, Assiut 71511, Egypt
Published online on: June 25, 2015 https://doi.org/10.3892/mco.2015.589
Pages: 995-1000
Copyright: © Taha et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As the δ-aminolevulinic acid dehydratase (ALAD) G177C polymorphism affects the toxicokinetics of lead in the body, and the corresponding exposure to lead may increase the risk of adult brain tumors, we hypothesize that there is a possible association of the ALAD G177C genotype and the risk of brain tumors in human. Therefore, the aim of the present study was to clarify the role of the ALAD enzyme gene polymorphism at position G177C in the pathogenesis of brain tumors and its correlation to lead exposure. The ALAD gene polymorphism at position G177C was genotyped using the polymerase chain reaction with restriction fragment length polymorphism method and measured the blood lead level by atomic absorption in 81 brain tumor patients and compared the results with 81 controls. The frequency of the GC genotype (ALAD1‑2) was significantly increased in primary brain tumor patients compared to the control group. The genotype frequency of ALAD2 (ALAD1‑2 and ALAD2‑2) was significantly higher in the meningioma patients but was not significant in glioma patients. There was no significant difference in the number of patients and blood lead level when compared with the control. There was a significant increase when compared to ALAD1 regarding a mean value of the lead level. The genotyping of the ALAD G177C polymorphism in the present study revealed a significant association between ALAD2 and brain tumors. The ALAD G177C polymorphism may modify the lead kinetics in the blood, is associated with higher blood lead burden and may provide a biomarker of neurotoxic risk.

View Figures

View References

1	Agency for Toxic Substances and Disease Registry (ATSDR), . Toxicological profile for lead. U.S. Department of Health and Human Services; Atlanta, GA USA: 1999
2	IARC WG, . IARC monographs on the evaluation of carcinogenic risks to humans: inorganic and organic lead compounds. Vol. 87. World Health Organization; Lyon, France: 2006
3	van Wijngaarden E and Dosemeci M: Brain cancer mortality and potential occupational exposure to lead: Findings from the National Longitudinal Mortality Study, 1979–1989. Int J Cancer. 119:1136–1144. 2006. View Article : Google Scholar : PubMed/NCBI
4	Navas-Acién A, Pollán M, Gustavsson P and Plato N: Occupation, exposure to chemicals and risk of gliomas and meningiomas in Sweden. Am J Ind Med. 42:214–227. 2002. View Article : Google Scholar : PubMed/NCBI
5	Cocco P, Heineman EF and Dosemeci M: Occupational risk factors for cancer of the central nervous system (CNS) among US women. Am J Ind Med. 36:70–74. 1999. View Article : Google Scholar : PubMed/NCBI
6	Steenland K and Boffetta P: Lead and cancer in humans: Where are we now? Am J Ind Med. 38:295–299. 2000. View Article : Google Scholar : PubMed/NCBI
7	Battistuzzi G, Petrucci R, Silvagni L, Urbani FR and Caiola S: delta-Aminolevulinate dehydrase: A new genetic polymorphism in man. Ann Hum Genet. 45:223–229. 1981. View Article : Google Scholar : PubMed/NCBI
8	Fujita H, Nishitani C and Ogawa K: Lead, chemical porphyria, and heme as a biological mediator. Tohoku J Exp Med. 196:53–64. 2002. View Article : Google Scholar : PubMed/NCBI
9	Shen XM, Wu SH, Yan CH, Zhao W, Ao LM, Zhang YW, He JM, Ying JM, Li RQ, Wu SM, et al: Delta-aminolevulinate dehydratase polymorphism and blood lead levels in Chinese children. Environ Res. 85:185–190. 2001. View Article : Google Scholar : PubMed/NCBI
10	Klaassen CD: Heavy metals and heavy-metal antagonistsGoodman & Gilman's the pharmacological basis of therapeutics. Brunton LL, Lazo JS and Parker KL: McGraw Hill; New York, NY: pp. 1753–1775. 2006
11	Villayandre BM, Paniagua MA, Fernández-López A and Calvo P: Effect of delta-aminolevulinic acid treatment on N -methyl-D-aspartate receptor at different ages in the rat brain. Brain Res. 1061:80–87. 2005. View Article : Google Scholar : PubMed/NCBI
12	Bellinger D, Hu H, Titlebaum L and Needleman HL: Attentional correlates of dentin and bone lead levels in adolescents. Arch Environ Health. 49:98–105. 1994. View Article : Google Scholar : PubMed/NCBI
13	Chia SE, Huijun Z, Theng TM and Yap E: Possibilities of newer ALAD polymorphism influencing human susceptibility to effects of inorganic lead on the neurobehavioral functions. Neurotoxicology. 28:312–317. 2007. View Article : Google Scholar : PubMed/NCBI
14	Rajaraman P, Schwartz BS, Rothman N, Yeager M, Fine HA, Shapiro WR, Selker RG, Black PM and Inskip PD: Delta-aminolevulinic acid dehydratase polymorphism and risk of brain tumors in adults. Environ Health Perspect. 113:1209–1211. 2005. View Article : Google Scholar : PubMed/NCBI
15	Lee BK, Lee GS, Stewart WF, Ahn KD, Simon D, Kelsey KT, Todd AC and Schwartz BS: Associations of blood pressure and hypertension with lead dose measures and polymorphisms in the vitamin D receptor and δ-aminolevulinic acid dehydratase genes. Environ Health Perspect. 109:383–389. 2001. View Article : Google Scholar : PubMed/NCBI
16	Miller DT, Paschal DC, Gunter EW, Stroud PE and D'Angelo J: Determination of lead in blood using electrothermal atomisation atomic absorption spectrometry with a L'vov platform and matrix modifier. Analyst (Lond). 112:1701–1704. 1987. View Article : Google Scholar
17	Wrensch M, Minn Y, Chew T, Bondy M and Berger MS: Epidemiology of primary brain tumors: Current concepts and review of the literature. Neuro Oncol. 4:278–299. 2002. View Article : Google Scholar : PubMed/NCBI
18	Benkmann HG, Bogdanski P and Goedde HW: Polymorphism of δ -aminolevulinic acid dehydratase in various populations. Hum Hered. 33:62–64. 1983. View Article : Google Scholar : PubMed/NCBI
19	Hsieh LL, Liou SH, Chen YH, Tsai LC, Yang T and Wu TN: Association between aminolevulinate dehydrogenase genotype and blood lead levels in Taiwan. J Occup Environ Med. 42:151–155. 2000. View Article : Google Scholar : PubMed/NCBI
20	Kelada SN, Shelton E, Kaufmann RB and Khoury MJ: Delta-aminolevulinic acid dehydratase genotype and lead toxicity: A HuGE review. Am J Epidemiol. 154:1–13. 2001. View Article : Google Scholar : PubMed/NCBI
21	Miyaki K, Lwin H, Masaki K, Song Y, Takahashi Y, Muramatsu M and Nakayama T: Association between a polymorphism of aminolevulinate dehydrogenase (ALAD) gene and blood lead levels in Japanese subjects. Int J Environ Res Public Health. 6:999–1009. 2009. View Article : Google Scholar : PubMed/NCBI
22	Rajaraman P, Stewart PA, Samet JM, Schwartz BS, Linet MS, Zahm SH, Rothman N, Yeager M, Fine HA, Black PM, et al: Lead, genetic susceptibility, and risk of adult brain tumors. Cancer Epidemiol Biomarkers Prev. 15:2514–2520. 2006. View Article : Google Scholar : PubMed/NCBI
23	Silbergeld EK: Facilitative mechanisms of lead as a carcinogen. Mutat Res. 533:121–133. 2003. View Article : Google Scholar : PubMed/NCBI
24	Montenegro MF, Barbosa F Jr, Sandrim VC, Gerlach RF and Tanus-Santos JE: Ethnicity affects the distribution of delta-aminolevulinic acid dehydratase (ALAD) genetic variants. Clin Chim Acta. 367:192–195. 2006. View Article : Google Scholar : PubMed/NCBI
25	Fujihara J, Agusa T, Yasuda T, Soejima M, Kato H, Panduro A, Koda Y, Kimura-Kataoka K and Takeshita H: Ethnic variation in genotype frequencies of delta-aminolevulinic acid dehydratase (ALAD). Toxicol Lett. 191:236–239. 2009. View Article : Google Scholar : PubMed/NCBI
26	Scinicariello F, Murray HE, Moffett DB, Abadin HG, Sexton MJ and Fowler BA: Lead and delta-aminolevulinic acid dehydratase polymorphism: Where does it lead? A meta-analysis. Environ Health Perspect. 115:35–41. 2007. View Article : Google Scholar : PubMed/NCBI
27	Lacourt A, Cardis E, Pintos J, Richardson L, Kincl L, Benke G, Fleming S, Hours M, Krewski D, McLean D, et al: INTEROCC case-control study: Lack of association between glioma tumors and occupational exposure to selected combustion products, dusts and other chemical agents. BMC Public Health. 13:340–351. 2013. View Article : Google Scholar : PubMed/NCBI
28	Ziemsen B, Angerer J, Lehnert G, Benkmann HG and Goedde HW: Polymorphism of δ -aminolevulinic acid dehydratase in lead-exposed workers. Int Arch Occup Environ Health. 58:245–247. 1986. View Article : Google Scholar : PubMed/NCBI
29	Fleming DE, Chettle DR, Wetmur JG, Desnick RJ, Robin JP, Boulay D, Richard NS, Gordon CL and Webber CE: Effect of the delta-aminolevulinate dehydratase polymorphism on the accumulation of lead in bone and blood in lead smelter workers. Environ Res. 77:49–61. 1998. View Article : Google Scholar : PubMed/NCBI
30	Wetmur JG, Kaya AH, Plewinska M and Desnick RJ: Molecular characterization of the human δ -aminolevulinate dehydratase 2 (ALAD2) allele: Implications for molecular screening of individuals for genetic susceptibility to lead poisoning. Am J Hum Genet. 49:757–763. 1991.PubMed/NCBI
31	Mahaffey K, McKinney J and Reigart JR: Lead and compoundsEnvironmental toxicants, human exposures and their health effects. 2nd. Lippmann M: John Wiley and Sons, Inc; New York, NY: pp. 481–521. 2000
32	Shaik AP and Jamil K: A study on the ALAD gene polymorphisms associated with lead exposure. Toxicol Ind Health. 24:501–506. 2008. View Article : Google Scholar : PubMed/NCBI
33	Sobin C, Gutierrez M and Alterio H: Polymorphisms of delta-aminolevulinic acid dehydratase (ALAD) and peptide transporter 2 (PEPT2) genes in children with low-level lead exposure. Neurotoxicology. 30:881–887. 2009. View Article : Google Scholar : PubMed/NCBI
34	Süzen HS, Duydu Y, Aydin A, Işimer A and Vural N: Influence of the delta-aminolevulinic acid dehydratase (ALAD) polymorphism on biomarkers of lead exposure in Turkish storage battery manufacturing workers. Am J Ind Med. 43:165–171. 2003. View Article : Google Scholar : PubMed/NCBI
35	Yang Y, Wu J and Sun P: Effects of delta-aminolevulinic acid dehydratase polymorphisms on susceptibility to lead in Han subjects from southwestern China. Int J Environ Res Public Health. 9:2326–2338. 2012. View Article : Google Scholar : PubMed/NCBI